Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (6500)	5/8/1999 1:50:00 PM
From: VLAD	Respond to of 7041

Hank, Any one who really knows the science behind the treatment of ED knows that Vasomax doesn't stand a snow ball's chance in hell of being a successful product. With a success rate of only 13% above placebo in MILD to MODERATE cases how can any one really think that it can effectively compete with Vivagra? The safety problems with Vasomax will be no different than those seen today with Viagra ie the drugs ability to induce a generalized hypotensive effect that can put an "at risk" patient over the edge. As I said before, the FDA is under the gun after allowing fast track approval of Viagra and not including the "at risk" group in its clinical trials. Actually I'm still surprised that the FDA has not black boxed Viagra--certainly Pfizer's political clout via all the money they contribute to political campaigns and on Washington lobbyists(5th largest spender on Washington lobbyists) has given them carte blanche on what IMHO boils down to getting away with murder. Big K will deny this until he is blue in the face but then with him its all Russian politics(I lie to you. You lie to me. Everything is OK) any way.